Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial by Cooper, SA et al.
This Provisional PDF corresponds to the article as it appeared upon acceptance. Fully formatted
PDF and full text (HTML) versions will be made available soon.
Toward onset prevention of cognitive decline in adults with Down syndrome (the
TOP-COG study): study protocol for a randomized controlled trial
Trials 2014, 15:202 doi:10.1186/1745-6215-15-202
Sally-Ann Cooper (Sally-Ann.Cooper@glasgow.ac.uk)
Muriel Caslake (Muriel.Caslake@glasgow.ac.uk)
Jonathan Evans (Jonathan.Evans@glasgow.ac.uk)
Angela Hassiotis (a.hassiotis@ucl.ac.uk)
Andrew Jahoda (Andrew.Jahoda@glasgow.ac.uk)
Alex McConnachie (Alex.McConnachie@glasgow.ac.uk)
Jill Morrison (Jill.Morrison@glasgow.ac.uk)
Howard Ring (har28@cam.ac.uk)
John Starr (jstarr@staffmail.ed.ac.uk)
Ciara Stiles (Ciara.Stiles@glasgow.ac.uk)
Frank Sullivan (f.m.sullivan@nygh.on.ca)
ISSN 1745-6215
Article type Study protocol
Submission date 7 March 2014
Acceptance date 7 May 2014
Publication date 3 June 2014
Article URL http://www.trialsjournal.com/content/15/1/202
This peer-reviewed article can be downloaded, printed and distributed freely for any purposes (see
copyright notice below).
Articles in Trials are listed in PubMed and archived at PubMed Central.
For information about publishing your research in Trials or any BioMed Central journal, go to
http://www.trialsjournal.com/authors/instructions/
For information about other BioMed Central publications go to
Trials
© 2014 Cooper et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
http://www.biomedcentral.com/
Trials
© 2014 Cooper et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Toward onset prevention of cognitive decline in 
adults with Down syndrome (the TOP-COG study): 
study protocol for a randomized controlled trial 
Sally-Ann Cooper1* 
*
 Corresponding author 
Email: Sally-Ann.Cooper@glasgow.ac.uk 
Muriel Caslake2 
Email: Muriel.Caslake@glasgow.ac.uk 
Jonathan Evans1 
Email: Jonathan.Evans@glasgow.ac.uk 
Angela Hassiotis3 
Email: a.hassiotis@ucl.ac.uk 
Andrew Jahoda1 
Email: Andrew.Jahoda@glasgow.ac.uk 
Alex McConnachie4 
Email: Alex.McConnachie@glasgow.ac.uk 
Jill Morrison5 
Email: Jill.Morrison@glasgow.ac.uk 
Howard Ring6 
Email: har28@cam.ac.uk 
John Starr7 
Email: jstarr@staffmail.ed.ac.uk 
Ciara Stiles1 
Email: Ciara.Stiles@glasgow.ac.uk 
Frank Sullivan8 
Email: f.m.sullivan@nygh.on.ca 
1
 Institute of Health and Wellbeing, University of Glasgow, Mental Health and 
Wellbeing Unit, Gartnavel Royal Hospital, Administrative Building, 1055, Great 
Western Road, Glasgow G12 0XH, UK 
2
 Institute of Cardiovascular and Medical Sciences, University of Glasgow, 
McGregor Building, 2nd floor, Western Infirmary, Glasgow G11 6NT, UK 
3
 University College London, Bloomsbury Campus, Charles Bell House, 67-73 
Riding House Street, London W1W 7EY, UK 
4
 Robertson Centre for Biostatistics, University of Glasgow, Boyd Orr Building, 
Glasgow G12 8QQ, UK 
5
 Institute of Health and Wellbeing, University of Glasgow, General Practice and 
Primary Care, 1 Horselethill Road, Glasgow G12 9LX, UK 
6
 School of Clinical Medicine, University of Cambridge, Douglas House, 18b 
Trumpington Road, Cambridge CB2 2AH, UK 
7
 Alzheimer Scotland Dementia Research Centre, 7 George Square, Edinburgh 
EH8 9JZ, UK 
8
 Gordon F Cheesbrough Research Chair and Director of UTOPIAN, University 
of Toronto, North York General Hospital, 4001 Leslie Street, Toronto, ON M2K 
1E1, Canada 
Abstract 
Background 
Early-onset dementia is common in Down syndrome adults, who have trisomy 21. The 
amyloid precursor protein gene is on chromosome 21, and so is over-expressed in Down 
syndrome, leading to amyloid b (Ab) over-production, a major upstream pathway leading to 
Alzheimer disease (AD). Statins (microsomal 3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors), have pleiotropic effects including potentially increasing brain amyloid 
clearance, making them plausible agents to reduce AD risk. Animal models, human 
observational studies, and small scale trials support this rationale, however, there are no AD 
primary prevention trials in Down syndrome adults. In this study we study aim to inform the 
design of a full-scale primary prevention trial. 
Methods/Design 
TOP-COG is a feasibility and pilot double-blind randomized controlled trial (RCT), with a 
nested qualitative study, conducted in the general community. About 60 Down syndrome 
adults, aged ≥50 will be included. The intervention is oral simvastatin 40mg at night for 12 
months, versus placebo. The primary endpoint is recruitment and retention rates. Secondary 
endpoints are (1) tolerability and safety; (2) detection of the most sensitive neurocognitive 
instruments; (3) perceptions of Down syndrome adults and caregivers on whether to 
participate, and assessment experiences; (4) distributions of cognitive decline, adaptive 
behavior, general health/quality of life, service use, caregiver strain, and sample size 
implications; (5) whether Aβ42/Aβ40 is a cognitive decline biomarker. We will describe 
percentages recruited from each source, the number of contacts to achieve this, plus 
recruitment rate by general population size. We will calculate summary statistics with 90% 
confidence limits where appropriate, for each study outcome as a whole, by treatment group 
and in relation to baseline age, cognitive function, cholesterol and other characteristics. 
Changes over time will be summarized graphically. The sample size for a definitive RCT will 
be estimated under alternative assumptions. 
Discussion 
This study is important, as AD is a major problem for Down syndrome adults, for whom 
there are currently no effective preventions or treatments. It will also delineate the most 
suitable assessment instruments for this population. Recruitment of intellectually disabled 
adults is notoriously difficult, and we shall provide valuable information on this, informing 
future studies. 
Trial registration 
Current Controlled Trials ISRCTN Register ID: ISRCTN67338640 (17 November 2011) 
Keywords 
Alzheimer disease, Dementia, Down syndrome, Neuropsychology, Primary prevention, 
Simvastatin, Statin 
Background 
Down syndrome and dementia 
Adults with Down syndrome have a high prevalence of dementia of Alzheimer disease (AD) 
type from middle age onward [1,2]. Dementia is a highly disabling disorder that results in 
progressive deterioration, increasing dependency as well as health and social support resource 
consumption and, ultimately, premature death. It has an impact on adults with dementia and 
their family and friends and also is a source of major societal and economic costs. Down 
syndrome is the commonest cause of early-onset dementia, with 40% of adults with Down 
syndrome ages 50 years and older acquiring it [1,2]. Almost everyone with Down syndrome 
ages 40 and older has neuropathological changes due to AD [3]. Because the life expectancy 
of people with Down syndrome has increased rapidly, with the majority now living beyond 
50 years of age, preventive measures against AD are urgently needed. 
The amyloid precursor protein (APP) gene is located on chromosome 21 and thus is 
overexpressed in Down syndrome (trisomy 21), leading to amyloid β (Aβ) overproduction. 
Excess Aβ levels form insoluble plaques and are a major upstream pathway leading to AD 
[4]. This is thought to be the mechanism of action resulting in the very high rates of AD in 
adults with Down syndrome. The pathology of dementia in adults with Down syndrome 
differs from that in the general population. In the general population vascular dementia and 
dementia in AD often cannot be clinically differentiated. Indeed, an increasing body of 
knowledge suggests that vascular changes and AD pathology are interrelated [5,6]. In 
contrast, adults with Down syndrome develop a relatively “pure” form of AD that supports 
the “amyloid hypothesis” in the general population. This is so because people with Down 
syndrome have a remarkable resilience to atherosclerosis [7,8], possibly due to the 
cystathionine β synthase gene’s location on chromosome 21, which is overexpressed in Down 
syndrome. This leads to decreased homocysteine levels and thus reduced arteriosclerosis. As 
Down syndrome adults are atheroma-free [8], with low blood pressure [8], and have low 
vascular dementia rates, their dementia is a “pure” model of dementia in AD, unlike that in 
the general population. In view of the specific genetic differences in people with Down 
syndrome, the findings produced by trials in the general population cannot be extended to 
people with Down syndrome. There are currently no effective interventions to prevent 
dementia onset in routine clinical practice, but proof of concept has been established in older 
adults with Down syndrome [9]. 
Evidence to date on a role for statins in Alzheimer disease 
Normally, Aβ production is balanced by Aβ clearance via apolipoprotein E (ApoE) receptors 
and the low-density lipoprotein receptor (LDLR) [10]. LDL is bound by LDLR and taken 
into the cell ending where it is degraded, and cholesterol is made available for repression of 
microsomal 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, which is the 
rate-limiting step in cholesterol synthesis. Statins are HMG CoA reductase inhibitors and thus 
are plausible agents to use to reduce AD risk. Supporting evidence has been produced by 
experimental studies, observations of populations, case-controlled observational studies, 
prospective cohort studies, secondary prevention trials and small-scale primary prevention 
trials with high-risk groups, as described in the following paragraphs. 
The brain has high levels of cholesterol. Cholesterol is synthesized locally, and its 
elimination utilizes ApoE. Its synthesis modulates the production of Aβ. Individuals with the 
ApoE e4/4 allele are at particularly high risk for developing AD in both the general 
population and the population with Down syndrome, highlighting the role of Aβ. In the 
general population without dementia, ApoE e4 is associated with relative cognitive decline at 
age 79 years [11], but healthier lipid profiles, such as higher erythrocyte ω-3 polyunsaturated 
fatty acid content, are significant only in the absence of the ApoE e4 allele [12]. The 
hypothesized pathway link between lipid metabolism and AD is amyloid clearance by the 
LDLR family of proteins. Brain LDLR activity has been shown to be increased significantly, 
especially in astrocytes, by statin treatment [13]. The results of studies with experimental 
animal models have demonstrated that LDLR deficiency causes hypercholesterolemia, 
cerebral β-amyloidosis and learning deficits [14] and that statins improve learning and slow 
AD pathology development [15]. LDLR-deficient Tg2576 mice develop 
hypercholesterolemia and age-dependent cerebral β-amyloidosis [14]. In the study by Cao et 
al. [14], LDLR-deficient Tg2576 mice showed more spatial learning deficits than LDLR-
intact Tg2576 mice did after the manifestation of Aβ deposition. Although LDLR genotypes 
did not affect the expression level of the Aβ precursor protein transgene, there was a 
significant increase in Aβ deposition accompanied by an increase of APOE expression in 
LDLR-deficient Tg2576 mice. 
In humans, almost all the evidence to date is drawn from the general population rather than 
from people with Down syndrome. Rates of dementia in AD appear to be low in populations 
with low blood cholesterol levels and diets low in fat and cholesterol [16,17]. Some study 
researchers have reported that high cholesterol levels increase the risk of AD [18], although 
not all found this to be so [19]. However, brain cholesterol is synthesized locally, and it is 
unclear whether blood levels are a suitable proxy measure. 
Researchers in several case–control studies have reported a lower risk of dementia among 
statin users than among controls [20-26]. As highlighted in a recent Cochrane review [27], 
the earlier studies were challenged on indication bias. However, the finding in these studies 
has been replicated, despite recent improvements in access to health care for people with 
dementia. 
In several prospective cohort studies, including recent well-conducted, large-scale studies, 
investigators reported that the use of statins predicted reduced incidence of AD or was 
associated with trends toward slower cognitive decline [26,28-33] or reduced risk of 
hospitalization due to dementia [34]. The strength of association between statin use and 
reduction in incidence of AD has been shown to diminish with age [32]. Other study 
researchers have reported no associations of statin use with AD [25,35], but not all 
differentiated dementia in AD from vascular dementias. Additionally, the amyloid pathway 
may not be the major disease determinant in some cases. For example, the religious order 
study participants had an exceptionally high mean educational level of 18.2 years [36]. Also, 
as amyloid pathway irregularities are upstream of dementia development, the period of 
observation of statin treatment may not cover all of the at-risk period. Researchers in one 
study found that lifelong cognitive change data found statins did indeed protect against 
cognitive decline in a population at approximately 80 years age [37]. 
Only one study has been conducted on the use of statins in adults with Down syndrome. In it, 
the investigators studied the relationship between statin use and incident dementia in AD over 
the course of 5 years in a prospective US cohort of 123 participants ages 40 years and older 
[9]. The participants on statins had less than half the risk of incident dementia. In the same 
cohort, persons with measurements of Aβ42 in the middle or highest range were found to be 
more than twice as likely to have incident dementia and persons with Aβ levels in the highest 
third were more likely to die [38]. To the best of our knowledge, to date, no trials of statins 
with adults with Down syndrome have been reported and none are currently registered. 
With regard to trials involving the general population, authors of a recent Cochrane review 
found only two published statin RCTs for the primary prevention of dementia [27]: the 
MRC/BHF Heart Protection Study (HPS) [39] and the Prospective Study of Pravastatin in the 
Elderly at Risk (PROSPER) study [40]. The HPS investigators used brief telephone 
interviews to assess cognition and found no effect of simvastatin 40 mg OD versus placebo 
over the course of 5 years [39]. In the PROSPER study, which was of older people, the 
trialists did not report any benefits, on the basis of cognitive testing, from pravastatin 40 mg 
OD therapy over a mean course of 3.2 years [40]. However, their conclusions are not relevant 
to adults with Down syndrome, as the study participants were selected specifically for having 
vascular disease and/or vascular risk factors and not for Aβ overproduction. Also, in neither 
trial did the investigators study incident dementia in AD specifically, and cognitive measures 
were only secondary outcomes. Indeed, the HPS team did not collect baseline cognitive data, 
and good baseline cognitive ability was required in the PROSPER study (Mini Mental State 
Examination score >24). Researchers in smaller studies including “AD high-risk groups” 
have found benefits at 4 months and 6 months [41,42]. The investigators in an AD high-risk 
study, the European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) 
study, recruited 100 people ages 35 to 69 years who had a parent with AD and studied 
simvastatin 80 mg OD. After 9 months, no difference was found in change in cerebrospinal 
fluid (CSF) Aβ42, although the degree of change was influenced by the participant’s 
underlying risk profile [43]. 
In a small, secondary prevention randomized controlled trial (RCT), the investigators 
randomized 63 people with mild to moderate dementia in AD to atorvastatin 80 mg once 
daily (OD) or placebo and demonstrated slowing in cognitive decline in the statin group at 6 
and 12 months [44]. In a larger-scale, double-blind, placebo-controlled study (the LEADe 
study), researchers recruited 640 participants with mild to moderate dementia and tested the 
addition of atorvastatin 80 mg to treatment with a cholinesterase inhibitor. They found no 
difference in change in cognition between the intervention and control groups after 72 weeks 
[45]. Two large, placebo-controlled, secondary prevention trials are in progress: the 
statins/CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) study (investigating 
simvastatin 40 mg) and the UCSD Statin Study (investigating simvastatin 20 mg or 
pravastatin 40 mg). However, statins are theoretically more effective in primary than in 
secondary prevention, so the results of these studies will be less relevant to the study outlined 
in this protocol. Authors of two more reviews recently concluded that trials are indicated 
specifically when AD is due to amyloid overproduction [46,47]. This is exactly the situation 
in Down syndrome. Authors of a recent systematic review of statins and cognitive function 
found there is an absence of well-powered RCTs for most cognitive outcomes and concluded 
that larger and better-designed studies are needed [48]. 
Much of the literature on aging and dementia in the general population does not apply to the 
atheroma-free Down syndrome population. Given the exceedingly high prevalence of 
dementia in AD in the Down syndrome population, it is crucially important that trials with 
and for them be undertaken. 
Choice of statin and dose 
There is no Down syndrome literature to inform the choice of statin to investigate in a 
primary prevention study or to confirm whether its safety profile is similar to that in the 
general population. We therefore selected simvastatin on theoretical rather than empirical 
grounds for the following reasons: 
1. Simvastatin is more lipophilic than hydrophilic compared with other statins [49]; 
therefore, it crosses the blood–brain barrier more easily and hence is expected to be more 
effective than other statins. 
2. Simvastatin has a good safety record in the general population. Researchers in clinical 
trials have reported that myalgia occurred in 1.2% of participants who received 40 mg OD 
[50]. They also found no difference in muscle pain or weakness between participants 
treated with simvastatin 40 mg OD or placebo for 5 years or in the number who 
discontinued treatment due to musculoskeletal problems [39]. Adverse reactions increase 
at higher doses [51]; hence we chose to use 40 mg OD in our present study. The incidence 
of fatal rhabdomyolysis has been estimated at 0.12% per 1 million prescriptions on the 
basis of data derived from the US Food and Drug Administration databases and the 
National Prescription Audit Plus [50]. 
3. There is evidence derived from a general population pilot RCT to support our choice of 
simvastatin 40 mg OD. After 26 weeks, participants with mild, but not severe, dementia in 
AD taking simvastatin 80 mg OD compared with placebo had statistically significantly 
higher scores on the Mini Mental State Examination and significantly decreased CSF 
Aβ40 levels. The reduction was correlated with CSF reduction in the cholesterol 
metabolite 24S-hydroxycholesterol. In participants with severe dementia, the large 
proportion of Aβ deposited in amyloid plaques may explain why a reduction was not 
detected in CSF [52]. Additionally, 57 participants at high risk for AD showed 
improvements in verbal fluency and on working memory measures in a 4-month, double-
blind RCT of simvastatin 40 mg OD [41]. 
Neuropsychological test instruments 
High dementia incidence and caregiver-reported adaptive functional decline over time (that 
is, a proxy measure of decline) are well-reported in adults with Down syndrome. 
Neuropsychological test materials used specifically to measure cognitive decline necessarily 
must differ from the tests used with the general population, as adults with Down syndrome 
have preexisting cognitive deficits and therefore existing norms do not apply. Furthermore, 
when assessing longitudinal decline, floor effects on general population measures prevent 
change being registered. Researchers have attempted to phenotype the early stages and 
progression of dementia in the Down syndrome population with adapted or specially devised 
assessments [2,53-57]. Investigators in small-scale studies have found a pattern of 
deterioration similar to that in the general population, with memory problems being the first 
clinical marker [53,54]. However, recently, study researchers have suggested that deficits in 
executive function, characterized by planning problems, personality changes and 
development of problem behaviors, might predate other aspects [2,57,58] and stem from the 
frontal lobe problems associated with Down syndrome [2]. These studies are limited by small 
sample sizes. Researchers in several studies who have utilized a range of measures, 
principally in the domains of memory, attention and executive function, have investigated 
cognitive decline with aging in people with Down syndrome [53,56,59,60]. However, to the 
best of our knowledge, no longitudinal reports of more than a handful of participants with 
Down syndrome ages 50 years and older have been published. Although researchers who 
studied 322 adults with intellectual disabilities published normative data derived from the 
Neuropsychological Assessment of Dementia in Intellectual Disabilities (NADIID), their 
investigation included few people with Down syndrome 50 years of age and older, and very 
sparse published longitudinal data on cognitive decline in people in this age group [53]. 
We anticipate that performance on standardized tests of cognitive function will be a more 
accurate and sensitive measure of decline than caregiver-reported changes in adaptive 
function. Hence, phenotyping is important. In this study, we will delineate the instruments 
most sensitive for detecting change by assessing the distribution of scores cross-sectionally 
and over time in relation to age, baseline scores and other participant characteristics. Hence 
the results of this study will enable the development of a new battery of tools comprising 
those with the greatest utility for the early detection of decline. This is important in the 
planning of a full-scale, primary prevention RCT. 
Study aims 
The aims of the study are (1) to acquire data to design a full-scale multi-center RCT of 
simvastatin for the primary prevention of dementia in AD, (2) to test recruitment and 
retention strategies to inform future trials with this population, (3) to determine the best 
instruments to use in future studies measuring cognitive decline in adults with Down 
syndrome and (4) to investigate mechanisms, using Aβ42/Aβ40 measurements as a putative 
surrogate biological marker. Additionally, consent will be obtained for subsequent future 
longer-term follow-up by record linkage to routinely collected health data and for samples to 
be banked at the University of Glasgow for potential future research. 
Methods/Design 
Type of study 
The study is a double-blind RCT of 12 months of simvastatin 40 mg OD by mouth versus 
placebo. It includes a nested qualitative study. The flowchart shown in Figure 1 summarizes 
the study protocol. 
Figure 1 Flowchart of the study protocol. AE, Adverse event; APO E, apolipoprotein E; 
AR, Adverse reaction; CYP3A4, Cytochrome P450 3A4; GG&C, NHS Greater Glasgow & 
Clyde; OD, Once daily; RCT, Randomized controlled trial; SAR, Serious adverse reaction. 
1. The study will be randomized to determine if, in this population, participants and 
caregivers are willing to receive the intervention or placebo without knowing which is 
being administered. Randomization will be stratified for baseline characteristics known to 
influence cognitive decline (age <55 and ≥55 years and ApoE e4 genotype) or 
characteristicswhere there is some limited evidence of influence (cholesterol <5 mmol/L 
and ≥5 mmol/L) to prevent any imbalance in participant types between treatment groups. 
2. Semistructured interviews will be conducted with participant-caregiver dyads to gain an 
understanding of their views on their decision whether to participate and be randomized, 
and their assessment experiences. 
Research questions 
The research questions we will seek to answer are listed below. 
1. What are the trial recruitment and retention rates and recruitment sources? 
2. What are the rates of tolerability and safety of simvastatin 40 mg OD? 
3. Which instruments are the most sensitive for detecting early cognitive decline with the 
least floor effect in adults with Down syndrome adults? 
4. What are the perceptions of adults with Down syndrome and their caregivers regarding 
their decision whether to participate and be randomized and their assessment experiences? 
5. What are the distributions of the primary outcome measure (cognitive decline) and key 
secondary outcome measures (adaptive behavior, general health and quality of life, service 
use and caregiver strain) that would be used in a definitive RCT, and what are the sample 
size implications of these distributions? 
6. Is Aβ42/Aβ40 a biomarker for cognitive decline? 
7. Do the results support proceeding to a full RCT? 
The outcome measures we will use to answer each of the research questions listed above are 
described in the subsections that follow. 
Research question 1: feasibility 
1. The numbers screened and recruited each month over the course of the recruitment period 
2. A measure of the retention of participants in the study after 12 months 
3. The percentage of the total number of participants recruited from each source and the 
number of contacts with each source to achieve this (The source will be identified during 
the initial telephone call to assess suitability of inviting the person to participate. Each 
contact made will be recorded by the researcher and Scottish Primary Care Research 
Network staff documenting each contact on a contact recording sheet.) 
4. The number of participants recruited per base general population size. 
Research question 2: tolerability and safety 
1. Compliance will be assessed by counting returned tablets every 3 months. 
2. Blood will be taken to measure muscle enzyme levels 6 to 12 weeks after starting the 
simvastatin or placebo treatments. 
3. Interviews will be conducted every 3 months, in addition to recording spontaneously 
reported adverse events (AEs) using the standard sponsor’s AE standard operating 
procedure. 
Research question 3: identification of the most suitable cognitive measures 
On the basis of published data regarding measures of cognitive decline in people with Down 
syndrome, we have identified eight tests considered most likely to be sensitive to change. The 
tests are in the domains of memory, attention and executive function: 
1. Memory for Objects from the NADIID battery [53] 
2. Selective Attention Cancellation Task [60] 
3. Pattern Recognition Memory from the Cambridge Neuropsychological Test Automated 
Battery [61] 
4. Cats and Dogs test [56] 
5. Tower of London Test (a test of frontal lobe executive function recently adapted for adults 
with intellectual disabilities by our group) [62] 
6. Cued Recall Test [63] 
7. Category fluency [56] 
8. Story recall (adapted from the Rivermead Behavioural Memory Test for Children [64]) 
Scores at baseline and after 12 months of simvastatin or placebo treatment will be compared 
for each of these measures to identify which show the greatest degree of change over the 
period and have the greatest utility across the full range of intellectual disabilities. 
Research question 4: participant/caregiver perceptions 
Key themes will be identified from the semistructured interviews in the nested qualitative 
study to improve our understanding of participants’ perspectives about research participation 
and randomization, and their assessment experiences. The analysis will be guided by the 
framework approach [65]. 
Research question 5: effect size 
The measures described below will be used with the adults with Down syndrome at baseline 
and after 12 months of simvastatin or placebo treatment to determine the effect size by 
comparing the simvastatin group with the placebo group. 
The primary outcome measure will be cognitive decline (using the instruments outlined 
above) [53,60-64]. The secondary outcomes will be measured using the following 
instruments: 
1. American Association on Intellectual and Developmental Disabilities Adaptive Behavior 
Scale (to measure the adaptive function of persons with intellectual disabilities) [66] 
2. Townsend’s Disability Scale (to measure general health) [67] 
3. EQ-5D (the EuroQol 5-Dimension Questionnaire; to measure health outcomes and quality 
of life) (recently reviewed for use with people with intellectual disabilities [68]) 
4. Client Service Receipt Inventory (to measure demographics and extent of service use as 
well as social changes, such as changes in level of paid support, move to a nursing home 
or loss of day placement) (This instrument was designed for use with adults with 
intellectual disabilities and adults with mental illness.) [69,70] 
5. The 12-item General Health Questionnaire (to be given to the caregivers at baseline and 
after 12 months to compare the health and carer strain of caregivers of participants in the 
simvastatin group with caregivers of participants in the placebo group) [71]. 
Research question 6: biomarkers 
At baseline and after 12 months of simvastatin or placebo treatment, blood will be taken to 
measure Aβ40/Aβ42 levels for comparison between the simvastatin and placebo groups. 
Research question 7: recommendations for a full randomized controlled trial 
1. The size of the general population pool needed to recruit adults with Down syndrome for 
the full RCT will be determined on the basis of the rates of recruitment and study 
completion in this pilot study, combined with the treatment effect estimate and uncertainty 
regarding the estimate. Additionally, the sensitivity of the neuropsychological measures 
will inform this decision, in particular with regard to the floor effect with persons with the 
most severe intellectual disabilities; in other words, to provide information about the 
proportion of the recruited population for whom it was possible to detect and measure 
change and therefore the likely proportion who would need to be excluded based on their 
baseline assessment of intellectual function. 
2. This pilot study will consider the size of the geographical recruiting area required and 
hence the associated costs. The full RCT would not be appropriate if there were 
unexpected adverse safety effects identified in this pilot study, which we consider to be 
unlikely. 
Ethical considerations and consent 
The study was given a favorable opinion by the Scotland A Research Ethics Committee 
(REC). In keeping with this response, each potential participant’s capacity to decide whether 
to participate in the trial will be assessed through discussion of the study, which will be 
facilitated with the person’s caregiver. This discussion with each potential participant will 
include going through the information sheet, which will be designed for persons with 
intellectual disabilities. The discussion will include what their participation will involve and 
will inform them that they will not benefit personally from taking part and that they do not 
have to participate if they do not wish to. Any questions that the person or caregiver has will 
be discussed and answered. To assess the person’s ability to understand, retain and weigh 
information about whether to participate, the person with Down syndrome will be asked to 
say what they think the study is about and what it will involve if they take part. Individual 
informed consent will then be obtained from persons who demonstrate that they have a good 
grasp of the study and understand that they can choose whether to take part. For persons 
considered not to have full decision-making capacity to consent to participate in the trial, the 
informed consent of their legal representative, as defined in the Medicines for Human Use 
(Clinical Trials) Regulations 2004 (CTR), will be sought. A separate information sheet will 
be used with relatives and other legal representatives for this purpose. Participation in the 
qualitative component of the study will require a separate consent. The legal requirement for 
this in Scotland is to adhere to the Adults with Incapacity (Scotland) Act, 2000. Hence, 
capacity to consent is assessed as outlined above. Persons then consent for themselves if they 
have the decision-making capacity to do so; otherwise, consent is obtained from their welfare 
guardian or nearest relative (as defined in the Act). 
Statistical power 
Approximately 60 participants with Down syndrome ages 50 and older will be randomized. 
Recruitment feasibility will be assessed on the bases of the number of people identified per 
10,000 population and the percentages of those contacted who would like to participate, and, 
among those, the percentage who are eligible to participate. For example, if 200 individuals 
are contacted and 100 agree to be screened, from among whom 60 are eligible for 
randomization, then the overall recruitment rate will be 30% with a 90% confidence interval 
(CI) of 25% to 36%. This will be sufficiently accurate to allow planning for a larger RCT. 
Similarly, if 50 participants complete the 12-month follow-up, the retention rate will be 83% 
with a 90% CI of 73% to 91%. 
The variance of the rate of cognitive decline will be estimated to calculate the sample size 
required for a definitive RCT. The precision of this estimate is a function of the sample size 
in this pilot study. We think that a sample size of 50 participants from whom we gather 12-
month outcome data is appropriate at this stage to provide a variance estimate that is 
reasonably precise, without requiring that we recruit an excessively large sample. With 50 
participants, a 90% CI for the variance in the rate of cognitive decline will have a width of 
approximately 70% of the estimated variance. A smaller sample size in this pilot study would 
greatly increase the uncertainty in the variance estimate, whereas calculation of a more 
precise estimate could require considerably more participants. For example, halving the width 
of the 90% CI for the estimated variance would require 180 participants, which we believe is 
too large for a pilot study designed to show the feasibility of an RCT. 
Sample size for the qualitative study 
We do not know in advance how many interviews will be necessary to reach saturation (with 
no new themes emerging), but we will plan to interview ten dyads of participants with Down 
syndrome and their caregivers and will also attempt to recruit ten dyads of adults with Down 
syndrome and their caregivers who choose not to participate in the pilot RCT. It is possible 
that some dyads will agree to this single, semistructured interview despite having declined to 
participate in the pilot RCT. 
Participants and their recruitment 
For the RCT, we will recruit approximately 60 adults with Down syndrome ages 50 and 
older. Potential participants will be given or sent information packs and invited to reply to the 
research team if they are interested in further information about participating. 
Although all older adults with Down syndrome will be known to their primary care teams, it 
is likely that a more efficient recruitment strategy will combine primary care, registry-based 
and wider recruitment methods, with snow-balling. We will test recruitment using a 
multipronged approach in Greater Glasgow and Clyde, Lothian and Tayside utilizing the 
following resources: 
1. Scottish Primary Care Research Network 
2. Scottish Dementia Clinical Research Network 
3. Down Syndrome Scotland membership list 
4. Scottish Consortium for Learning Disabilities and their e-SAY project 
5. Professionals working within specialist intellectual disabilities health and social work 
services 
6. Larger provider organizations of 24-hour support packages and specialist day care 
If the recruitment rate is lower than anticipated within the first 2 months of recruitment 
initiation, then approvals will be sought to expand recruitment efforts into other areas of 
Scotland utilizing the same methods. If interest to participate in the study is high, we will 
recruit the first 60 suitable participants while continuing to measure the response rate. To 
judge the most effective means of recruitment, during the screening call to gauge each 
individual’s eligibility to participate in the study, we will inquire if the person knows the 
source of the information pack they received which resulted in their replying for more 
information about the study. 
Two groups of participants will be selected for the qualitative study. They will be drawn from 
among (1) those who participated in the RCT and (2) those who declined to participate in the 
RCT or did not respond to the invitation to participate. For the first group, we will try to 
avoid bias by purposively sampling ten participants and their caregivers (including people 
across the range of ability levels of intellectual disabilities and paid and family caregivers) 
who had baseline assessments during the first 3 months of recruitment (maximum variance 
sampling). For the second group, we will also attempt to recruit ten Down syndrome and 
caregiver dyads who did not take up the invitation to participate in the pilot RCT. We will 
attempt to recruit people with family caregivers, people with paid caregivers and people 
across the range of ability levels of people with intellectual disabilities, but we acknowledge 
that there may in limitations in how successful we will be with this second group. 
Inclusion and exclusion criteria 
The inclusion criteria are (1) a diagnosis of Down syndrome and (2) age 50 years or older. 
The exclusion criteria are listed below: 
1. No consent obtained 
2. Unable to comply with the protocol, including providing blood or saliva for baseline 
ApoE e4 measurement and venous or capillary blood for cholesterol measurement 
3. Dementia at baseline (as the study is investigating primary prevention) 
4. Diabetes (as this is an indication for prescription of a statin) 
5. Clinically evident atherosclerotic disease (as this is an indication for prescription of a 
statin) 
6. Being at risk for cardiovascular disease (as this is an indication for prescription of a statin) 
7. Liver disease 
8. Chronic renal insufficiency 
9. Currently being prescribed any of the following: 
a. A statin 
b. Fibrates 
c. Nicotinic acid 
d. Cyclosporine 
e. Triazole antifungals, including fluconazole, itraconazole, posaconazole, ketoconazole, 
voriconazole, miconazole oral gel, verapamil) 
f. Macrolide antibiotics (including erythromycin, clarithromycin, telithromycin) 
g. Danazol 
h. Fusidic acid 
i. HIV protease inhibitors (for example, nelfinavir, nefazodone, verapamil, amiodarone, 
warfarin, diltiazem, amlodipine) 
j. Moderate CYP3A4 inhibitors (if the person lives alone or has only part-time paid 
support) 
k. Hepatitis C protease inhibitors (for example, boceprevir, telaprevir) 
 
10. Previous serious adverse reaction to a statin 
11. Unable or unwilling to avoid consumption of grapefruit juice 
12. Excessive alcohol use (defined as >21 U/wk for men and >14 U/wk for women) 
Group allocation and blinding 
Participants will be randomly assigned to either simvastatin or placebo and stratified by age, 
ApoE e4 allele and cholesterol level. After collecting baseline data and samples, the 
researcher will notify the Robertson Centre for Biostatistics (RCB) of the participant’s study 
number and age via the web portal. The laboratory will notify the RCB of the participant’s 
ApoE status and cholesterol level, also via the web portal. The RCB will then notify the 
pharmacy of group allocation and generate an email to the research assistant notifying him or 
her that randomization has taken place as well as of the medication pack number assigned. 
The pharmacy will then dispense the medication. A verifiable audit trail will be ensured. The 
research assistant will telephone participants to check whether the medication has arrived and 
instructions are fully understood. The research team will therefore remain blinded to both 
ApoE and group allocation status, as will the participants and their caregivers. Medications 
will be dispensed within 4 weeks of baseline data collection. This time frame will allow for 
batching of the ApoE analyses. 
Duration of participation 
Participation 
Each participant’s participation in the study will last for 12 months postrandomization unless 
they withdraw prematurely. 
Completion 
The date of completion for safety is defined as the last dose of simvastatin or placebo plus 30 
days. For other study outcomes, each participant will be considered to have completed the 
study either after the completion of the last assessment visit or after receiving the last dose of 
simvastatin or placebo, whichever is later. The date of discontinuation will be recorded as the 
date on which a participant and/or investigator determines that the participant can no longer 
comply with the requirements for any further study visits or assessments. 
Assessments 
Assessments and blood tests will be conducted either in the person’s own home or at another 
venue if the participant/caregiver prefers. Home visits will be offered in order to increase 
recruitment and retention and for the convenience of the participants and caregivers, as well 
as to conduct the psychometric tests as accurately as possible by conducting them in a 
familiar, comfortable environment for the participant. 
Intervention 
The intervention is simvastatin 40 mg at night by oral administration. The simvastatin will be 
overencapsulated. The control group will receive an oral placebo capsule at night by mouth. 
The capsules are to be swallowed whole, not chewed. Dose modifications are not allowed. A 
summary of product characteristics is available, as is an Investigational Medicinal Product 
Dossier. The drug and placebo will be prepared by the Pharmacy Production Unit based at the 
Western Infirmary in Glasgow. 
Unblinding procedure 
Unblinding will be permitted in emergencies where, for medical or safety reasons, it is 
necessary to know which treatment a participant has received. Study participants will be 
provided with a Participant Alert Card that will include the name of the investigational study 
drug, their study number, the investigator’s name and a 24-hour telephone number for 
unblinding purposes. Unblinding will be done via a telephone menu system. Several prompts 
in the system will warn the user that he or she is required to be a health professional and that 
name and other pertinent information must be recorded. At each unblinding, an email alert to 
the Chief Investigator will be generated. Requests will be set at a maximum of two per 24 
hours to prevent malicious unblinding. The Participant Alert Card will be collected from 
participants at the end of their involvement in the study. 
Expected adverse reactions 
The expected adverse reactions are listed below. There is no theoretical reason to expect a 
higher rate in adults with Down syndrome. 
1. Myalgia 
2. Myositis 
3. Rhabdomyolysis 
4. Flulike symptoms 
5. Fatigue 
6. Headache 
7. Nausea 
8. Diarrhea 
9. Fatal and nonfatal hepatic failure 
10. Raised HbA1c and fasting glucose 
11. Diabetes mellitus 
12. Cognitive impairment (rarely) 
Definitions of muscular adverse reactions 
1. Alanine aminotransferase and aspartate aminotransferase elevation will be defined as more 
than three times the upper limit of normal. 
2. Myalgia is defined as muscle ache or weakness without creatine kinase (CK) elevation. 
3. Myositis is defined as muscular symptoms with a CK level more than ten times the upper 
limit of normal. 
4. Rhabdomyolysis is defined as a CK level >10,000 U/L with or without muscular 
symptoms. 
All AEs and intercurrent illnesses will be recorded, notified, reported, analyzed and managed 
in accordance with the CTR. The research sponsor’s standard operating procedures for 
recording and reporting AEs and serious AEs will be followed. An annual safety report will 
be submitted to the Medicine and Healthcare Products Regulatory Agency and the REC 
within 60 days of the anniversary of the issue of the clinical trial’s authorization. Safety data 
will be measured through three monthly telephone interviews. 
Data analysis 
Recruitment 
During the initial phone call, we will identify the source to which the person responded. We 
will describe the percentage of the total recruited from each source and the number of 
contacts with each source required to achieve this total (via diary records). We will also 
calculate recruitment by base general population size. 
Pilot randomized controlled trial 
A detailed statistical analysis plan will be prepared prior to the unblinding to treatment 
allocations, according to the RCB/Glasgow Clinical Trials Unit standard operating 
procedures. Briefly, summary statistics will be presented, with 90% confidence limits where 
appropriate, for each study outcome as a whole, by treatment group and in relation to baseline 
participant characteristics. Changes in outcomes over time will be summarized and presented 
graphically. The treatment effect estimate is of interest, not so much in terms of the 
magnitude or statistical significance of effect (the sample size is too small to draw definitive 
conclusions in this study), but rather regarding the uncertainty in this estimate or the 
variability in the rate of cognitive decline from which this estimate is derived. It is this 
variability estimate that will inform the sample size for a definitive trial, along with 
information about likely recruitment and retention rates. Statistical results will be interpreted 
in terms of the implications for a definitive RCT; for example, the sample size (and cost) 
required for screening and randomization will be estimated under alternative assumptions 
based on the pilot data. In additional analyses, we will examine outcomes of cognitive decline 
in relation to age, ApoE status, baseline cognitive function, cholesterol level and other 
baseline characteristics, which may provide information useful in defining the target 
population in future studies. We intend to apply exploratory factor analysis and other data 
reduction methods to examine interrelationships between different cognitive measures and 
their changes over time. The data gathered will not be sufficient to propose alternative 
outcome measures based on this analysis, but we may be able to propose novel hypotheses to 
be tested in a larger study. 
Qualitative study 
Topic guides will be used in the semistructured interviews, but they will be flexible. They 
will focus on the issues that potential study participants consider when deciding whether to 
take part in the study and, after the study, what made taking part a positive or negative 
experience for them. The interviews will be tape-recorded and transcribed verbatim. The 
analysis will be guided by the framework approach [63]. As such, the analytic process will be 
deductive in that it will be guided by the aims of the study, but it will simultaneously be 
inductive and flexible and thereby allow key themes to emerge. The tape-recorded interviews 
will be transcribed as close to the time of the interview as possible, and the researcher’s field 
notes will be checked to ensure accurate transcription. Analysis will begin during the 
interview period so that any themes which arise can be verified in later interviews. The 
researcher will review the transcripts to identify the key issues of importance for participant-
caregiver dyads. The first four transcripts will be analyzed independently by a second 
member of the research team who is blinded to the themes identified by the researcher to 
ensure consistency of identification of themes and that the identified themes are an accurate 
reflection of the material. The results will be fed back to the participant-caregiver dyads to 
find out if they concur with our findings. The themes will be used to make suggestions about 
how to revise and/or improve the study processes for participants. 
Discussion 
We think this study is important, as dementia is such a major problem for adults with Down 
syndrome. At present, there are no interventions that have been found to be effective for them 
in either preventing dementia or treating it. This feasibility/pilot study is the first step toward 
informing a large-scale RCT to determine whether simvastatin is effective in preventing or 
delaying the onset of dementia in this group. Additionally, the findings are likely to be 
relevant to clinical practice as well as to future research because, at present, there is no 
neuropsychological test battery accepted as best practice for use with adults with Down 
syndrome. This study will provide information on the instruments that may be useful in this 
regard. In view of the age range of the participants (50 years and over), the study should be 
more informative about neuropsychological test instruments than previous work with younger 
adults with Down syndrome. The study will allow us to determine whether our battery of 
cognitive tests is sensitive to cognitive decline over a 1-year period in the placebo group. 
Recruitment is often a challenge in general population trials [72]. The authors of a Cochrane 
review on strategies to improve recruitment concluded that (1) trialists should include 
evaluations of their recruitment strategies and (2) funders should support these evaluations 
because the number of interventions that have been rigorously evaluated in the context of a 
real trial is low [73]. Recruitment of adults with intellectual disabilities is notoriously 
difficult. They are routinely excluded from general population medication trials, and very few 
trials have been designed specifically for them. There are challenges in conducting research 
with this group, and recruitment may be atypical [74,75]. In an antipsychotic drug study of 
adults with intellectual disabilities with aggressive behaviors, the investigators had 
substantial recruitment problems but excellent retention rates. Only 72% of the intended 
participant numbers were recruited, despite an increase in recruitment time from 2 to 4 years 
and an extension of study sites [75]. Previous studies of rivastigmine and donepezil with 
adults with Down syndrome were small in scale and of short duration and the participants 
recruited were adults younger than proposed in our protocol; hence they were less 
challenging to recruit than in our study because of the larger pool of potential participants for 
those studies [76,77]. As the participants in the previous studies cited already had dementia, 
the motivation of the participants and their caregivers might conceivably differ from that of 
the potential participants in our study, who will be disease-free. In a larger study of 
memantine, participants were recruited over a 2.5-year period in England and Norway. They 
included adults at the younger age of 40 years and people who did and did not have dementia; 
hence recruitment was less challenging than in our study [78]. The likely recruitment and 
retention rates with this population in the age range chosen for our study are unknown and 
might be atypical. There is not a body of research to understand the choices made by older 
persons with Down syndrome and their caregivers regarding research, as well as what 
motivates them whether to participate, their perceptions regarding randomization and their 
experiences in the studies. Concerns about what randomization is and what then happens to 
participants may be significant blocks to recruitment; hence an important part of this study is 
to better understand these perceptions with a view toward minimizing them in future studies. 
These knowledge gaps will be addressed in this study, which should provide valuable 
information on recruitment and retention to inform future studies. 
Trial status 
We will complete recruitment in June 2014. 
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